Prostate cancer-specific five-year survivals were 90.92%, 69.19% and 76.31%, respectively, and 10-year survivals were 82.72%, 41.74% and 65.76%, respectively in the PSA-screened, PSA-screened with later diagnosis, and clinically diagnosed groups (Figure 4b, P<0.0001). This evidence concerns the gene KLK3 and Familial prostate cancer.